Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for TOVX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -3.085M
March 31, 2026 -2.456M
December 31, 2025 -2.882M
September 30, 2025 -4.319M
June 30, 2025 -4.712M
March 31, 2025 -4.756M
December 31, 2024 -4.691M
September 30, 2024 -3.913M
June 30, 2024 -3.452M
March 31, 2024 -4.881M
December 31, 2023 -6.541M
September 30, 2023 -2.953M
June 30, 2023 -3.892M
March 31, 2023 -5.61M
December 31, 2022 -5.368M
September 30, 2022 -4.456M
June 30, 2022 -4.356M
March 31, 2022 -4.902M
December 31, 2021 -4.81M
September 30, 2021 -2.156M
June 30, 2021 -2.596M
March 31, 2021 -3.328M
December 31, 2020 -3.132M
September 30, 2020 -2.05M
June 30, 2020 -2.026M
Date Value
March 31, 2020 -4.96M
December 31, 2019 -3.605M
September 30, 2019 -3.062M
June 30, 2019 -2.982M
March 31, 2019 -4.224M
December 31, 2018 -3.29M
September 30, 2018 -3.602M
June 30, 2018 -4.308M
March 31, 2018 -6.079M
December 31, 2017 -3.932M
September 30, 2017 -4.524M
June 30, 2017 -5.74M
March 31, 2017 -6.008M
December 31, 2016 -10.38M
September 30, 2016 -5.983M
June 30, 2016 -5.86M
March 31, 2016 -5.674M
December 31, 2015 -10.97M
September 30, 2015 -15.21M
June 30, 2015 -7.25M
March 31, 2015 -5.458M
December 31, 2014 -4.779M
September 30, 2014 -4.535M
June 30, 2014 -3.295M
March 31, 2014 -3.47M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Ironwood Pharmaceuticals, Inc. 58.28M
Nkarta, Inc. -24.22M
Unicycive Therapeutics, Inc. -7.604M
OnKure Therapeutics, Inc. -10.35M
ACADIA Pharmaceuticals, Inc. 100.78M